Sartorius Stedim Biotech S.A./ADR (SDMHF)
Sartorius Stedim Biotech S.A. engages in the production and sale of instruments and consumables for the biopharmaceutical industry worldwide. The company offers various products, such as cell lines; cell culture media; bioreactors; reagents; advanced therapies; and a range of products for separation, purification, and concentration processes, as well as products and systems for storage and transportation of intermediate and finished biological products. It also provides fluid management services; biolayer interferometry instruments; microbiology testing, sterility testing, and air monitoring instruments; pipette products; sensors and analyzers; screening instruments; biomolecule analysis tools; batch liquid chromatography systems; lab data and fleet management software; live cell imaging and analysis; surface plasmon resonance solutions; water purification systems; and weighing products. In addition, the company offers data analytics software; process automation platform and software; and transfection reagents and plasmid DNA solutions. The company has a collaboration with Bio Usawa Biotechnology, Ltd. focusing on developing and manufacturing monoclonal antibodies in Sub-Saharan Africa to tackle oncology, diabetes-induced eye diseases, infectious diseases, and autoimmune conditions. It serves manufacturers of medications, vaccines, food, and chemicals, as well as research and development laboratories. The company was incorporated in 1978 and is headquartered in Aubagne, France. Sartorius Stedim Biotech S.A. is a subsidiary of Sartorius AG.
Industry: Medical - Instruments & Supplies
Sartorius Stedim Biotech S.A.
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
FRSartorius Stedim Biotech S.A. serves as a leading global supplier, providing essential equipment and expendable materials to the biopharmaceutical industry.
The company's comprehensive product lineup supports a broad spectrum of bioprocesses, including cell culture growth media, diverse cell lines, and advanced bioreactor systems.
It also offers specialized solutions for isolating, purifying, and concentrating biological substances, alongside systems designed for the secure storage and transport of both intermediate and finished biological products. Moreover, Sartorius Stedim Biotech develops innovative single-use and reusable hollow-fiber membrane devices, as well as pre-sterilized assemblies specifically tailored for cutting-edge cell and gene therapy applications. Their portfolio extends to tools for cell harvesting and various other sophisticated solutions aimed at enhancing the efficiency of bioprocesses. Complementing its hardware, the company provides analytical software engineered to model and optimize critical stages of biopharmaceutical development and production. Beyond its product offerings, Sartorius Stedim Biotech delivers comprehensive services in areas such as cell cultivation, fermentation, filtration, purification, and fluid management.
Its diverse clientele encompasses manufacturers across the pharmaceutical, food, and chemical sectors, in addition to numerous research and development institutions. Established in 1870 and headquartered in Aubagne, France, the organization operates as a subsidiary of Sartorius AG.
Leadership
Rene Faber
Chief Executive Officer & Director
Petra Muller
Head of Investor Relations
Employees
10K+
Country
FR
Sector
Healthcare
Website
sartorius.com
FR30d Avg
2.65K
60d Avg
5.21K
90d Avg
4.32K